12:00 AM
 | 
Nov 01, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

Niaspan niacin-based product regulatory update

The FDA granted marketing approval to Niaspan to increase HDL cholesterol in patients with dyslipidemia....

Read the full 51 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >